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Abstract
Background: Primary aldosteronism (PA) is the most common form of secondary hypertension, while
Gitelman’s syndrome (GS) is the most common inherited renal tubular disease. However, coexistence of
these two diseases has never been previously reported.
Aim and subjects: The aim of our study was to describe the association of GS and PA in two unrelated
patients and compare their clinical presentation with a group of patients with GS.
Methods: Ten subjects suspected to have only GS were assigned to the control group. Saline infusion test
was used to confirm the diagnosis of PA. GS was confirmed by sequencing of the causal genes
(SLC12A3 and CLCNKB) and functional analyses in Xenopus laevis oocytes.
Results: Confirmatory tests, gene analysis, and functional studies demonstrated the coexistence of GS
and PA in both patients. In total, nine novel SLC12A3 gene variants, including seven missense
mutations, one splice mutation, and one frameshift deletion, were found in 12 subjects. Four
mutations (p.T60M, p.T304M, p.T465P, and p.N611T) harbored by the two patients with both PA and
GS were revealed to be loss-of-function variants. Although both patients were normotensive, neither of
them had normal nocturnal dip.
Conclusions: Two rare diseases GS and PA may occasionally coexist in one subject. In these patients, salt
depletion and volume constriction might explain the absence of hypertension normally seen in PA
patients. However, the protective mechanism against hypertension via down-regulation of renal
sodium handling was probably not sufficient in those patients, since their normal circadian rhythm of
blood pressure was disrupted.
European Journal of Endocrinology 161 275–283
Introduction
Primary aldosteronism (PA) is the most common form of
secondary hypertension. Its prevalence among hyper-
tensive patients may exceed 10%, as demonstrated by a
large prospective survey (1).
Gitelman’s syndrome (GS; OMIM #263800), an
autosomal-recessively inherited renal salt-losing
disorder, is mainly caused by mutations in the
SLC12A3 gene (MIM: 600968) (2), which encodes the
thiazide-sensitive Na–Cl cotransporter (NCC) (3).
Additionally, a few patients with GS-like phenotype
carry mutations in CLCNKB gene (MIM: 602023)
(4, 5). GS is the most common primary renal tubular
disease, with a prevalence of about 1 per 40 000 (6).
Theoretically, by chance only, the coexistence of PA
and GS in one patient should be very rare
(w1/2 500 000), given the prevalence of hypertension
at about 17%. Indeed, according to our knowledge, the
coexistence has never been documented so far. Herein,
we report two cases with the coexistence of both
diseases and attempt to explore the potential
mechanism(s) under their special clinical features.
Subjects and methods
Patients
A 39-year-old married male (patient 1) was admitted
for frequent muscle cramps that had occurred in the
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recent 4 months. Twelve years ago, he was once
referred to our outpatient clinic for an examination of
generalized muscle weakness associated with acral
paresthesia. At that time, his blood chemistry showed
persistent hypokalemia (1.7–2.6 mmol/l), in associ-
ation with alkalosis (plasma bicarbonate, 29–
32 mmol/l), inappropriate kaliuresis (fractional
excretion potassium (FEK): 31%), and salt losing (24 h
urinary Na, 261 mmol, normal values, 137–
257 mmol). Plasma renin activity (PRA, 11.1 ng/ml
per h, normal values, 0.1–2.9 ng/ml per h) and plasma
aldosterone concentration (PAC, 17.2 ng/dl, normal
values, 2.9–16.1 ng/dl) were elevated. Renal ultra-
sound findings were normal. Casual blood pressure (BP)
averaged 105/70 mmHg. The association of hypoka-
lemic alkalosis, renal salt loss, and hyperreninemic
hyperaldosteronism associated with normotension led
us to suspect a diagnosis of Bartter’s syndrome (BS).
This patient did not comply with regular therapy except
for intermittent administration of potassium chloride.
After hospitalization this time, his physical and
biochemical indices were revaluated (Tables 1 and 2).
The laboratory findings of hypomagnesemia, with a
magnesium level of 0.31–0.44 mmol/l, and hypocal-
ciuria (urine calcium/creatinine (Ca/Cr): 0.06–
0.1 mmol/mmol), suggested a diagnosis of GS. Repeated
examinations demonstrated his suppressed PRA and
elevated PAC. The PAC/PRA ratio was extremely high
(Table 2). Thus, the collective evidence of renal salt loss
and unexpectedly suppressed PRA led to the suspicion of
coexistence of PA and GS in this patient. Computerized
tomography showed bilateral enlarged adrenal glands
(data not shown). None of his family members had
hypokalemia and hypertension.
Patient 2 was a 42-year-old woman who was
hospitalized because of persistent muscle weakness for
5 years. She was first diagnosed as GS according to
electrolytes analysis of her serum and urine. However,
the suppressed PRA, elevated level of PAC, and high
PAC/PRA ratio also raised our suspicion of her
coexistence of PA (Table 2). No positive renal and
adrenal gland image findings were detected. All her
family members had normal levels of serum potassium
and BP.
To make the diagnosis of these two patients clear, and
compare their biochemical features with GS, we selected
ten age- and body mass index-matched subjects (six
males and four females) with only GS as controls. They
came from nine unrelated families, and their age ranged
from 34 to 46 years (mean 39G4 years). Their gross
clinical features and biochemical data were shown in
Tables 1 and 2. Criteria for GS diagnosis were: serum
magnesium level!0.65 mmol/l, serum potassium level
lower than 3.5 mmol/l, and hypocalciuria (urinary
Ca/Cr ratio !0.1 mmol/mmol).
All subjects had normal renal function, and claimed
no laxatives or diuretics abuse. Informed consent was
obtained from each subject and the study protocol was
approved by the ethics committee of the affiliated
hospital, Qingdao University School of Medicine.
Office BP and ambulatory blood pressure
monitoring
Office BP was measured with a mercury sphygmoman-
ometer after the patient had rested by sitting for at least
5 min according to AHA guidelines (7) with the mean of
two readings used for analysis. All patients also
underwent non-invasive ambulatory blood pressure
monitoring (ABPM; Spacelabs model 90207; Spacelabs
Inc., Richmond, WA, USA). The monitor recorded
systolic and diastolic BP every 20 min during the
daytime (0600–2200 h) and every 30 min at night
(2200–0600 h). Nocturnal decline was defined as the
percentage difference in ambulatory day versus night
BP levels. Dippers were defined as patients with R10%
decline in both systolic and diastolic BP.
Saline infusion test and adrenal venous
sampling
Sodium intake was unrestricted. After overnight
recumbency, 2 l of 0.9% saline solution were adminis-
tered intravenously in 4 h between 0800 h and noon.
BP and heart rate were monitored closely during the
test. PRA and PAC were measured before and after the
test. Adrenal venous sampling (AVS) was carried to
identify the lateralization of aldosterone secretion.
Mutation analysis
Genomic DNA was extracted from peripheral blood of
these two patients, control subjects, their family
members, and 200 normal healthy controls by the
GenElute blood genomic DNA kit (Sigma, NA2010).
SLC12A3 and CLCNKB genes were analyzed as
described (8, 9). To analyze transcriptional profiles for
Table 1 Clinical characteristics of the two patients and control
subjects.
Patients suspected
of PA and GS (nZ2)
Clinical
characteristics Patient 1 Patient 2
Control
subjects with
only GS
(nZ10)
Male/female 1/1 6/4
Age (years) 39 42 39G4
Body mass index (kg/m2) 26.5 21 23.6G2.2
Systolic office BP (mmHg) 135 130 112G10*
Diastolic office BP (mmHg) 85 80 71G9.1
Systolic 24-h BP (mmHg) 129 126 105G9*
Diastolic 24-h BP (mmHg) 79 76 65G6*
Dipper/non-dipper 0/2 9/1*
*P!0.05.
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the SLC12A3-splicing mutations, we extracted total
RNA from blood using TRIzol (Invitrogen/Gibco). After
DNAase treatment, RNA was purified with the Total
RNA Purification System (Invitrogen) and was reverse
transcribed with Superscript III (Invitrogen). After the
detection of a substitution at or close to a splice
consensus sequence, exonic pairs of primers were
designed as described (10) to amplify cDNA regions.
One primer of each pair was used to sequence the PCR
product. As the pathophysiology of normotensive
primary hyperaldosteronism is unknown and has
shown wide phenotypic variability among carriers of
the chimeric CYP 11-b/aldosterone synthase gene (11),
we carried out a genetic analysis of these two patients to
rule out a peculiar clinical presentation of dexametha-
sone (DXM)-sensitive hyperaldosteronism. The presence
of the CYP11B1/CYP11B2 chimeric gene was studied
using the long PCR technique introduced by Jonsson
et al. (12).
Functional studies of SLC12A3 mutations
NCC-directed mutagenesis and in vitro human NCC
cRNA translation Four mutations identified in these
two patients were selected for functional analysis
(T60M, T304M, T465P, and N611T). Wildtype (WT)
human NCC (hNCC) cDNA was cloned into pT7TS
vector (kindly provided by Dr Paul Krieg, University of
Texas) using the restriction sites of BgIII and SpeI. A
FLAG epitope tag was added at the 5 0 site of NCC to
facilitate detection. Site-directed mutagenesis (Quik-
ChangeII XL Site-Directed Mutagenesis Kit, Stratagene,
La Jolla, CA, USA) was performed according to the
manufacturer’s instructions. Direct sequencing of the
full-length cDNA was performed to confirm mutagen-
esis. The four mutant constructs were linearized with
EcoRI, and cRNA transcripts were synthesized in vitro
using T7 RiboMAX Express System (Promega). Tran-
scription product integrity was confirmed on agarose
gels, and concentration was determined by absorbance
reading at 260 nm (Gene Quant a, Pharmacia Biotech).
Expression studies in Xenopus laevis oocytes
Oocytes at stages V–VI were obtained from X. laevis
(13). Each oocyte was injected with either 50 nl water
or 10 ng WT or mutated hNCC cRNAs. 22NaC uptake
assay, western blotting, and immunocytochemistry
were performed as described (13) after 48 h of
incubation. Assessment of tracer 22NaC uptake (New
England Nuclear, Waltham, Massachusetts, USA) was
determined in groups of at least 15 oocytes. Oocytes
were transferred to ClK free medium for 24 h and
next transferred to 500 ml uptake medium (containing
1 mCi/ml 22NaC, 1 mM ouabain, 100 mM bumetanide,
and 100 mM amiloride) for 2 h at 32 8C. At the end of
the uptake period, oocytes were washed five times in
ice-cold uptake solution without the isotope to remove
extracellular fluid tracer. After the oocytes were
dissolved in 10% (w/v) SDS, tracer activity was
determined for each oocyte by b-scintillation counting.
Western blotting was used to compare WT and mutant
hNCC protein in cRNA-injected oocytes. Isolation of
total membranes was performed in 15 oocytes. Protein
samples were immunoblotted onto PVDF membranes
and successively incubated with 1:8000 dilution mouse
anti-FLAG (Sigma) and 1:2000 diluted sheep HRP
conjugated to anti-mouse IgG (Sigma) antibodies, bands
were detected by using ECL system (Pierce, Rockford, IL,
USA). The subcellular localization of hNCC was
determined in immunocytochemical analyses. To the
end, the remaining vitelline membrane was removed
after 48 h of incubation, and oocytes were fixed at room
temperature for 2 h at room temperature in 1% (w/v)
Table 2 Biochemical summary of the two patients and control
subjects.
Patients suspected
of PA and GS (nZ2)
Biochemical
data Patient 1 Patient 2
Control
subjects
with only
GS (nZ10)
Normal
range
Serum levels of electrolytes
Na (mmol/l) 140 142 138G3.3 130–147
K (mmol/l) 2.1 2.2 2.54G0.35* 3.5–5.1
Cl (mmol/l) 97 93 96G2.9 95–108
Mg (mmol/l) 0.42 0.46 0.49G0.08 0.7–1.0
Blood gas analysis
pH 7.50 7.46 7.45G0.03 7.35–7.45
HCO3 (mmol/l) 31 29 29.1G1.54 22–27
Urinary electrolytes analysis
Urinary Na
(mmol/24 h)
196 187 237G53 137–257
Urinary Cl
(mmol/24 h)
227 204 250G56 170–250
Fractional
excretion of
K (%)
36 29 24.6G7.4* 8–12%
Urinary
Ca/Cr ratio
(mmol/mmol)
0.04 0.06 0.043G0.02 0.2–0.6
PRA (ng/ml per h)
Supine PRA !0.1 (0.2)a 0.3 13.0G8.9† 0.1–2.9
Standing PRA 0.23 1.1 18.7G11.9† 0.6–11.0
PAC (ng/dl)
Supine PAC 25.6 16.2 18.5G3.9 2.9–16.1
Standing PAC 51.6 39.1 38.8G6.1 3.8–31.3
PAC/PRA ratio
Supine 128 81 1.76G0.8†
Standing 224 35.5 2.3G1.2†
Saline infusion test
PAC before
test (ng/dl)
22.9 21.5 16.9G4.1
PAC after test
(ng/dl)
18.7 20.4 5.1G1.3†
All biochemical data of each subject were the mean of three examinations
except the values of saline infusion test. To convert from metric units to
International units, multiply PAC by 28 and PRA by 0.28. PRA, plasma renin
activity; PAC, plasma aldosterone concentration. *0.05!P!0.1, †P!0.01.
aWhen calculating the PAC/PRA ratio, we arbitrarily fix the lowest PRA value
at 0.2 ng/ml per h to avoid overinflating the value.
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paraformaldehyde fixative, dehydrated, and paraffined.
Six micrometer thick sections were cut and incubated
overnight at 4 8C with mouse anti-FLAG antibody
(Sigma) diluted 1:200 followed by incubation at room
temperature for 1 h with Alexa fluor 488 goat anti-
mouse IgG (Invitrogen) diluted 1:250.
Statistical analysis
The biochemical data were expressed as meanGS.D. The
Student’s unpaired t-test and c2 test were used to
compare the differences between these two patients
suspected of having both PA and GS and control subjects
with only GS. P!0.05 was considered statistically
significant, while 0.05!P!0.1 was borderline
significant.
Results
As shown in Table 1, both patients 1 and 2 had normal
values of office BP and mean 24-h BP. However,
their systolic and 24-h diastolic BP levels were
significantly higher than control subjects with only GS
(Table 1). In addition, ABPM confirmed that neither
patients had normal nocturnal dip (Figs 1 and 2), while
nine out of ten subjects had normal circadian rhythm
in control group (PZ0.045; Table 1). The mean
ambulatory BP of patient 1 was 129/79 mmHg (mean
diurnal pressure 128/78 mmHg; mean nocturnal
pressure 131/81 mmHg), and the value of patient
2 was 126/76 mmHg (127/77 mmHg by day and
121/73 mmHg by night).
Laboratory data are shown in Table 2. Both patients
presented persistent hypokalemia, hypomagnesemia,
hypocalciuria and increased renal salt excretion as
seen in subjects with only GS. However, they had
borderline significant lower serum potassium level
(PZ0.08) and borderline significant higher FEK
(PZ0.07) than patients with only GS.
The most distinctive feature in these two patients was
their suppressed PRA levels as shown in Table 2.
Repeated examinations demonstrated that the first
patient had severe suppressed PRA and elevated PAC.
The PAC/PRA ratio was extremely high. The levels of
supine and standing PRA of patient 2 were within
normal range, though at the low limit of normal range.
The level of her PAC was higher than normal value, and
her PAC/PRA ratio was higher than the cut-off value
(30 ng/dl per ng/ml per h), which was often used to
screen PA. By contrast, in the control group, the PRA of
each subject was higher than the upper normal range,
and the decline of PAC was significantly higher than
these two patients after saline infusion. Additionally, it is
worth noting that PAC levels of each subject in the
control group were!10 ng/dl, while PAC levels of both
patients in the study group were above that value.
AVS was carried to identify the lateralization of
aldosterone secretion. The plasma aldosterone levels
from the right and left adrenal veins and the inferior
vena cava of patient 1 were 592.3, 458.8, and
38.7 ng/dl, and the cortisol levels were 106.0, 126.1,
and 16.5 mg/dl respectively (Table 3). Adrenal vein
cannulation was considered successful given that the
bilateral adrenal vein/inferior vena cava cortisol
gradients were 6.4 and 7.6 respectively. The ratio of
the higher to lower levels of aldosterone in the right and
left adrenals (aldosterone ratio) was 1.3, aldosterone to
cortisol ratio (A/C ratio) in the right and left adrenals
were 5.6 and 3.6 respectively, and the ratio of higher to
lower levels of A/C ratio in the right and left adrenals
(lateralization index, LI) was 1.56. The data of patient
2 were also available in Table 3, her LI was 1.19.
After 2 months of potassium and magnesium
supplementation together with spironolactone
(50 mg/day) treatment, serum potassium levels in
both patients could reach the low limit of normal level
(w3.5 mmol/l). As shown in Figs 1 and 2, ABPM
demonstrated that the mean value of 24-h BP slightly
decreased by nearly 10 mmHg, and the normal
circadian rhythm characterized with nocturnal dip
was restored in both patients. The mean 24-h BP of
patient 1 was 117/69 mmHg (diurnal: 121/71 mmHg;
nocturnal: 106/61 mmHg), while the value of
Figure 1 Patient 1: results of ambulatory blood pressure monitoring
(ABPM) before and after treatment. Top panel: before treatment by
spironolactone. The mean ambulatory BP was 129/79 mmHg; the
circadian rhythm was disrupted with a mean diurnal pressure of
128/78 mmHg and a mean nocturnal pressure of 131/81 mmHg.
Bottom panel: after treatment by spironolactone. The 24-h BP
slightly decreased byw10 mmHg with the mean 24-h BP of
117/69 mmHg. The normal circadian rhythm characterized with
nocturnal dip reappeared with a mean diurnal pressure of
121/71 mmHg and a mean nocturnal pressure of 106/61 mmHg.
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patient 2 was 120/70 mmHg (122/72 mmHg by day
and 110/65 mmHg by night) by ABPM. The decrease of
BP in night time was more predominant than that in
day time in both patients.
Sequence analysis of the SLC12A3 gene of these two
patients and ten control subjects revealed 16 different
punctual mutations (Supplementary Table, which can
be viewed online at http://www.eje-online.org/supple-
mental/ and Fig. 3A), including nine novel mutations
(Supplementary Figure, which can be viewed online
at http://www.eje-online.org/supplemental/). The novel
variants are seven missense mutations (p.C146F,
p.T304M, p.N359D, p.T465P, p.P556L, p.N611T, and
p.Y857C), a deletion of a guanine (c.402delG) that
caused a frameshift that resulted in a truncated
polypeptide with 141 acid residues (p.Arg135AlafsX8),
and a splice mutation (c.964C2TOC), which was
confirmed to lead to a shorter transcript characterized
as skipping exon 7 by cDNA sequencing (p.Ala285
ArgfsX48). Additionally, seven mutations (p.T60M,
p.G439S, p.S555L, p.R655C, p.R928C, p.Thr114A-
lafsX142, and p.Arg959SerfsX11) identified in this
study had been reported previously (8, 10, 14–20). To
both patients suspected of PA and GS, patient 1 showed
compound heterozygosity for mutations of p.T60M and
p.T304M, patient 2 was also a compound heterozygote
with variants of p.T465P and p.N611T. In the control
group, only one mutant allele was identified in two
subjects. All mutations co-segregated with the pheno-
type, and all missense mutations identified in this study
are substitute amino acids that are highly conserved in
all transporter proteins belonging to the protein super-
family of cotransporters (NCCT, NKCC1, NKCC2).
Sequence analysis for the above-mentioned 16 hNCC
mutations revealed heterozygous p.T60M in 2, p.R928C
in 1, p.Thr114AlafsX142 in 1, and p.Arg959SerfsX11
in 2 out of 200 unrelated healthy subjects respectively.
No CLCNKB gene mutation was found and gene tests
ruled out DXM-sensitive hyperaldosteronism.
To further determine whether those mutations will
affect hNCC’s functionality, we used the Xenopus oocytes
model system. As Fig. 3C shows, we observed in a
western blot from oocytes expressing WT and mutant
hNCC, which mutants of p.T304M and p.T465P
produce proteins that are not fully glycosylated with a
single band of 110 kDa, whereas p.T60M and p.N611T
generate proteins in which glycosylation patterns
appear indistinguishable from WT with bands 110
and 130–140 kDa. The results of 22NaC uptake assay
were demonstrated in Fig. 3B; the p.T60M, p.T304M,
and p.T465P mutants showed the same level of activity
as H2O-injected oocytes, whereas mutant p.N611T
showed a rate of 22NaC uptake of 54%, compared
with oocytes that expressed the WT protein. As
displayed in Fig. 3D, in sections of oocytes expressing
WT hNCC, clear immunostaining at the plasma
membrane was observed, whereas staining was absent
in H2O-injected oocytes. Sections of oocytes expressing
the mutant p.T60M exhibited similar pattern with WT,
and those expressing p.T304M and p.T465P mutants
demonstrated predominant intracellular staining, with
only minor staining at the plasma membrane, whereas
those expressing mutant p.N611T revealed significant
immunopositive staining of both the plasma membrane
and the cytoplasm. These results indicate that among
Table 3 Adrenal venous sampling in the two patients.
Patient 1 2
Aldosterone (ng/dl)
Right 592.3 399.4
Left 458.8 423.4
Higher/lower 1.3 1.06
IVC 38.7 23.1
Cortisol (mg/dl)
Right 106.0 107.8
Left 126.1 96.3
IVC 16.5 13.8
Cortisol ratio (AV/IVC)
Right 6.4 7.8
Left 7.6 7.0
Aldosterone to cortisol ratio
Right 5.6 3.7
Left 3.6 4.4
Higher/lower (LI) 1.56 1.19
IVC, inferior vena cava; AV/IVC, adrenal vein/inferior vena cava ratio;
LI, lateralization index.
Figure 2 Patient 2: results of ambulatory blood pressure monitoring
(ABPM) before and after treatment. Top panel: before treatment by
spironolactone. The mean ambulatory BP was 126/76 mmHg; the
circadian rhythm without sufficient normal dipper was shown with
a mean diurnal pressure of 127/77 mmHg and a mean nocturnal
pressure of 121/73 mmHg. Bottom panel: after treatment by
spironolactone. The 24-h BP slightly decreased by nearly 10 mmHg
with the mean 24-h BP of 120/70 mmHg. The circadian rhythm
characterized with normal nocturnal dipper restored with a mean
diurnal pressure of 122/72 mmHg and a mean nocturnal pressure
of 110/65 mmHg.
Renal salt-losing disease and adrenal hyperplasia 279EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009) 161
www.eje-online.org
the four mutations studied, p.T304M and p.T465P are
not complex glycosylated, absent from the plasma
membrane, and nonfunctional. The mutant p.N611T
exhibit complex glycosylation, presence in both the
plasma membrane and the cytoplasm, and an inter-
mediate level of activity compared with WT. Although
the mutant p.T60M show complex glycosylation and
similar cell surface expression with WT, its intrinsic
activity was abolished.
Discussion
In this report, we described two rare cases presenting
with features of GS such as normotensive, hypokalemia,
hypomagnesemia, hypocalciuria, and hyperaldosteron-
ism. However, the unexpectedly suppressed PRA made
the diagnosis elusive. To confirm the coexistence of GS
and ‘autonomous’ hyperaldosteronism in both patients,
we performed a series of studies, such as SLC123 gene
analysis, functional studies, and saline infusion test.
The diagnosis of GS was confirmed by genetic tests
and functional studies besides their clinical and
biochemical features in both patients. All the four
variants of p.T60M, p.T304M, p.T465P, and p.N611T
found in them were confirmed to be potentially
pathogenic to GS by functional studies in Xenopus
oocytes. Among the four mutant sites in hNCC, Thr60
has recently been revealed to be the key activating
phosphorylation site on NCC, and played an important
role in the activation of NCC (21). Our study
demonstrated that hNCC harboring mutant p.T60M
almost completely lost its intrinsic activity without
affecting the surface expression. These results were
similar with the expression study by Pacheco-Alvarez
et al. on rat NCC carrying mutant p.T58A (Thr58
equivalent to Thr60 in hNCC) (22). It is noteworthy
that mutant p.T60M has been frequently reported to be
correlated with GS (8, 10, 14–17). In fact, it was the
most common mutation in Asian populations so far. At
codon 611, another mutant, p.N611S, caused by an A-
to-G substitution at nucleotide 1832 (c.1832AOG), has
also been proven to have decreased activity compared
with WT based on an in vitro study (23). Therefore,
it appears that the substitution of asparagine by
threonine at codon 611 has a similar effect on NCC
function as the substitution by serine.
Saline infusion test demonstrated that aldosterone
secretion was independent, at least partially, from
renin–angiotensin system in both patients, whereas
the production of aldosterone was significantly sup-
pressed by saline infusion in the control group. There-
fore, integration of the results of gene analysis,
functional studies, and saline infusion tests suggested
concurrence of PA and GS in both patients. The
exploitation of the type of hyperaldosteronism in these
two patients was interesting. Aldosterone-producing
adenoma (APA) and idiopathic hyperaldosteronism
(IHA) are two major subtypes of PA. APA, also termed
as Conn’s adenoma, is a surgically curable disease.
Figure 3 Functional studies of missense mutations in SLC12A3. (A) Schematic of the thiazide-sensitive Na–Cl cotransporter (NCC) and
missense mutations identified in this study. The NCC is represented as a 12-transmembrane-domain protein with intracytoplasmic amino
and carboxyl termini. The sites of mutations are denoted by arrows, the mutations underlined are novel variants, the remainders are found
by others. *Position of the selected mutations for functional study. (B) Immunoblots of total membrane extracts that were isolated from
Xenopus oocytes, either H2O-injected (H2O) or injected with 10 ng WT or mutant hNCC mRNA. (C)
22NaC uptake in oocytes that expressed
WT or mutant hNCC. Uptake values are shown as percentage of the WT, where 100% represents an uptake of 2.8 nmol NaC/oocyte per
2 h. ***P!0.0001 in relation to the uptake of H2O-injected oocytes. (D) Representative immunocytochemistry of oocytes injected with WT
or mutant hNCC: plasma membrane staining in an oocyte injected with WT hNCC (a similar pattern was observed for p.T60M; a); H2O-
injected oocyte with only background staining (b); oocyte expressing nonfunctional p.T304M mutant with intracellular staining only (a similar
pattern was observed for p.T465P1); c); oocyte injected with functional p.N611T mutation that presented both plasma membrane and
intracellular staining (d).
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However, IHA could be improved by mineralocorticoid
receptor (MR) antagonist. Only APA can be unequi-
vocally diagnosed with strict criteria such as evidence of
adenoma at pathological examination besides bio-
chemical evidence of PA and lateralization of aldoster-
one secretion at AVS. However, no such diagnostic
gold standard exists for identifying IHA. Therefore, we
could not obtain conclusive diagnosis as neither of them
suffered adrenalectomy. Luckily, a recent investigation
by Rossi et al. (24) has calculated an optimal LI cut-off
value of 1.98, which provided the best trade-off between
sensitivity (79.5%) and specificity (75%) for exclusion of
APA. With decrease in LI cut-offs from 1.98 to 1.125,
the possibility (about 20%) of having APA further
decreased steadily. From the statistical data provided by
Rossi et al. the AVS results suggested that both patients
(with LI 1.56 and 1.19 respectively) very likely had IHA
other than APA.
The classic form of PA is characterized by hyperten-
sion and hypokalemia. Recent statistical data have
demonstrated that more than one half of patients with
PA were normokalemia (1). Although the hypertension
is usually mild and may fluctuate, only 27 cases with
consistently normotensive, due to APA or IHA, have
been reported so far (25–27). The mechanism(s)
underlying the maintenance of normal BP levels, despite
an overproduction of aldosterone, are unknown. It is a
well-acceptable hypothesis that aldosterone-induced
salt retention and volume expansion may be the prime
factor to hypertension in PA, and meanwhile an
important contributor to the development of hyperten-
sion in the long term (28, 29). GS is a salt-losing disease
due to the loss of function of NCC in the distal
convoluted tubule. Salt depletion and volume constric-
tion are the main pathophysiologic characteristics of
GS. Coexistence of salt-losing disease might just explain
the absence of hypertension in these two patients with
PA and give further evidence to the above-mentioned
hypothesis. In addition, angiotensin II (Ang II) is one of
the most important humoral factors involved in the
vascular alterations in hypertension. It is well known
that Ang II leads to vasoconstriction and cardiovascular
remodeling via its complex intracellular signaling
pathways, such as activation of Gq protein signal,
along with down-regulation of nitric oxide (NO) system
and the up-regulation of RhoA/ROK pathway. Extensive
studies of patients with GS performed by Calo` et al. have
shown that cellular pathways induced by Ang II are
blunted (30). This explained well the reduced peripheral
resistance, vascular hyporeactivity, and normo-
hypotension in GS patients, in spite of high Ang II and
activation of the renin–angiotensin–aldosterone system
(RAAS). The plasma levels of Ang II in PA patients are
suppressed; however, the local RAAS may play a more
important role in the development of hypertension.
Therefore, the mechanisms maintaining normal BP
by blunting Ang II signaling may also exist in these
two patients.
However, ABPM proved disrupted circadian rhythm
of BP in both patients, with mild nocturnal hyperten-
sion in patient 1, and the level of nocturnal BP in
patient 2 was at the upper limit of normal ambulatory
BP (normal!120/70 mmHg). This suggested that the
protective mechanism against hypertension via down-
regulation of renal sodium handling was probably not
sufficient in patients with PA. This situation resembles
that of secondary hypertension such as aldosteronism,
which is more often than not resistant to diuretics. It is
well known that hyperaldosteronism is associated with
endothelial dysfunction and impaired vascular reactiv-
ity in patients with hypertension (31). When present,
endothelial dysfunction is an independent predictor of
adverse cardiovascular events. The MR antagonist
spironolactone restored both patients’ normal BP
circadian rhythm and reduced their BP to optimal
level. We supposed that this occurs, in part, as a result of
improved vascular function. In addition, the diagnosis
of PA in both patients was further confirmed by the
response to treatment with spironolactone.
It is interesting that the secondary aldosteronism
coexisting with GS in patient 1 progressed to PA within
12 years. However, the precise underlying mechanism is
difficult to elucidate since the pathogenesis of PA is still
unknown. It should also be noted that both patients
probably had IHA rather than APA. It is well known
that APA and IHA had different physiological aldoster-
one regulation, as evidenced by the APA’s ACTH
responsiveness and holding to be functionally autono-
mous from the renin–angiotensin system, conversely,
IHA still maintain the normal regulation of adrenocor-
tical zona glomerulosa. This suggests the existence of an
alternative etiology under the descriptive term of ‘IHA’.
Whether IHA is tertiary hyperaldosteronism remains
controversial (28, 32, 33). Theoretically, the underlying
mechanism for tertiary hyperaldosteronism is persistent
stimulation of the adrenal by excessive Ang II, causing
aldosterone overproduction, which eventually evolves
into an autonomous phase (28, 34). However, the
existence of tertiary hyperaldosteronism has been strongly
challenged by Conn et al. who reviewed five cases of
primary reninism associated with juxtaglomerular
tumors. They noted that two patients had been exposed
to prolonged hyperreninemia for many years, and
that after surgical intervention, both showed a decline
in aldosterone excretion. They recommended that the
term ‘tertiary’ hyperaldosteronism be abandoned (33).
Recently, Lim et al. have again proposed that it
is feasible to redefine IHA as a form of tertiary
aldosteronism by incorporating new data (28). On the
other hand, they considered that polymorphisms of
the aldosterone synthase gene may play a part in the
development of hyperaldosteronism, and suggested that
individuals with certain polymorphisms may be predis-
posed to the development of tertiary hyperaldosteronism
(28, 32). Since both PA and GS are not common
diseases, the coexistence of these two diseases may be
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due to chance; however, this does not completely rule
out the possibility that IHA in these two patients is also
acquired under the condition of lasting stimulation
factors (salt, Ang II, etc.) that interact with predisposing
genes over a long time. Therefore, the evolution from
secondary aldosteronism to PA in patient 1 might be
well explained by the acquired or tertiary hyperaldos-
teronism. However, it is worth noting that only two
cases were found in nearly 100 GS patients we
encountered, and the vast majority of subjects did not
evolve to the autonomous phase of aldosteronism under
the long-term stimulation of Ang II and therefore, the
possibility of existence of ‘tertiary’ hyperaldosteronism
is very low.
In summary, these two cases illustrate that both PA
and GS may rarely occur in the same patient. It is
noteworthy that either disorder may be initially
discovered although GS was discovered initially in our
patients. We propose that careful excluding exami-
nation should be done to explore the possibility of
existence of renal-salt-losing disease such as GS in a
patient with normotensive PA, and vice versa, PA should
be considered in a patient with renal salt-losing disease
and jointly with suppressed PRA.
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